- Home
- NDLS vs BTAI Comparison
NDLS vs BTAI Comparison
Compare NDLS & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NDLS | BTAI |
|---|---|---|
| Founded | 1995 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.7M | 35.6M |
| IPO Year | 2013 | 2018 |
Fundamental Metrics
Financial Performance| Metric | NDLS | BTAI |
|---|---|---|
| Price | $8.03 | $1.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 135.4K | ★ 882.0K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.63 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $495,089,000.00 | N/A |
| Revenue This Year | N/A | $141.28 |
| Revenue Next Year | N/A | $1,921.56 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.37 | N/A |
| 52 Week Low | $0.47 | $1.08 |
| 52 Week High | $9.95 | $8.08 |
Technical Indicators
Market Signals| Indicator | NDLS | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 62.18 | 30.91 |
| Support Level | $0.62 | N/A |
| Resistance Level | $9.95 | $1.77 |
| Average True Range (ATR) | 0.73 | 0.12 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 49.62 | 6.07 |
Price Performance
Historical ComparisonAbout NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.